NCT02252016View on ClinicalTrials.gov

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)

PHASE3CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

October 22, 2014

Primary Completion Date

December 7, 2015

Study Completion Date

June 14, 2016

Conditions
Hepatitis C
Interventions
DRUG

Grazoprevir + Elbasvir

FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.

DRUG

Placebo

Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02252016 - Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065) | Biotech Hunter | Biotech Hunter